Perrigo Company plc (PRGO) to Issue Quarterly Dividend of $0.29 on September 15th

Perrigo Company plc (NYSE:PRGO) announced a quarterly dividend on Thursday, July 30th. Investors of record on Friday, August 28th will be given a dividend of 0.29 per share on Tuesday, September 15th. This represents a c) dividend on an annualized basis and a dividend yield of 8.0%. The ex-dividend date is Friday, August 28th.

Perrigo has increased its dividend payment by an average of 0.1%per year over the last three years and has raised its dividend every year for the last 23 years. Perrigo has a dividend payout ratio of 35.5% meaning its dividend is sufficiently covered by earnings. Research analysts expect Perrigo to earn $2.41 per share next year, which means the company should continue to be able to cover its $1.16 annual dividend with an expected future payout ratio of 48.1%.

Perrigo Stock Performance

Shares of Perrigo stock opened at $14.48 on Wednesday. The stock’s fifty day simple moving average is $11.22 and its 200 day simple moving average is $11.42. The company has a current ratio of 2.32, a quick ratio of 1.32 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $2.01 billion, a PE ratio of -1.16, a PEG ratio of 1.63 and a beta of 0.51. Perrigo has a 12 month low of $9.23 and a 12 month high of $24.04.

Perrigo (NYSE:PRGO) last posted its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.11. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.02 billion. Perrigo had a positive return on equity of 11.25% and a negative net margin of 41.85%.The company’s revenue was down 3.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.06) earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, research analysts predict that Perrigo will post 2.2 EPS for the current year.

Institutional Trading of Perrigo

Hedge funds and other institutional investors have recently modified their holdings of the company. Geneos Wealth Management Inc. boosted its position in shares of Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after buying an additional 786 shares during the period. Kestra Investment Management LLC raised its position in Perrigo by 57.1% in the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after buying an additional 642 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Perrigo by 116.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after acquiring an additional 1,014 shares in the last quarter. UMB Bank n.a. lifted its stake in Perrigo by 161.5% in the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after acquiring an additional 1,213 shares in the last quarter. Finally, Meeder Asset Management Inc. acquired a new position in Perrigo during the 4th quarter worth approximately $28,000. Institutional investors and hedge funds own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.